Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comparing inhaled corticosteroids.

G L Colice1

  • 1Pulmonary, Critical Care, and Respiratory Services, Washington Hospital Center, DC 20010, USA.

Respiratory Care
|August 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asthma severity categorization using a claims-based algorithm or pulmonary function testing.

The Journal of asthma : official journal of the Association for the Care of Asthma·2009
Same author

Economic burden of pneumonia in an employed population.

Archives of internal medicine·2001
Same author

Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma.

The Journal of asthma : official journal of the Association for the Care of Asthma·2001
Same author

Impact of noninvasive studies to distinguish volume overload from ARDS in acutely ill patients with pulmonary edema: analysis of the medical literature from 1966 to 1998.

Chest·2000
Same author

Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline.

Chest·2000
Same author

Proventil HFA prevents exercise-induced bronchoconstriction in children.

The Journal of asthma : official journal of the Association for the Care of Asthma·1999
Same journal

Active Warming Using Heated Inspired Gas: Full of Hot Air?

Respiratory care·2026
Same journal

Work of Breathing by the Campbell Diagram: Physiology and Practice.

Respiratory care·2026
Same journal

Inhaled Sedation in the ICU.

Respiratory care·2026
Same journal

Risk Stratification Using the Tracheostomy Early Prediction Score and the Association Between Early Tracheostomy and Mortality in Sepsis.

Respiratory care·2026
Same journal

Editor's Commentary.

Respiratory care·2026
Same journal

Response to the Letter to the Editor Regarding "Comparative Evaluation of Risk Scores for Predicting Postoperative Pulmonary Complications".

Respiratory care·2026
See all related articles

New inhaled corticosteroids and devices are emerging. Estimating clinical benefits and adherence impact from product data alone is challenging for respiratory care practitioners. Well-designed trials are essential for comparisons.

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Multiple inhaled corticosteroids (ICS) and delivery devices are available.
  • Newer ICS and inhalation devices are anticipated in the US market.
  • Extensive data on potency, pharmacokinetics, and usability will accompany new products.

Purpose of the Study:

  • To highlight the challenges respiratory care practitioners face when evaluating new inhaled corticosteroids.
  • To emphasize the need for careful interpretation of data regarding clinical benefits and patient adherence.
  • To advocate for the use of well-designed clinical trials in comparing ICS.

Main Methods:

  • This is a conceptual review and does not present original research data.
  • The abstract discusses the expected information landscape for new inhaled corticosteroids.

Related Experiment Videos

  • It emphasizes the importance of clinical trial data over product-specific metrics.

    • Main Results:

    • Information on potency, pharmacokinetics, and device usability may not directly translate to clinical benefits.
    • The impact of improved device ease-of-use on patient adherence to inhaled corticosteroid therapy is difficult to ascertain from technical data alone.
    • Clinical trials are necessary to accurately assess the comparative efficacy and adherence impact of different ICS.

    Conclusions:

    • Respiratory care practitioners must critically evaluate data provided for new inhaled corticosteroids and devices.
    • Estimating true clinical utility requires data beyond potency and pharmacokinetic profiles.
    • Well-designed clinical trials are the gold standard for comparing inhaled corticosteroids and understanding their real-world effectiveness.